Loading
Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials.
Bempegaldesleukin is a PEGylated IL-2 prodrug biased toward the CD122 receptor to expand CD8 T cells over regulatory T cells. Phase 1/2 PIVOT-02 with nivolumab reported high response rates in melanoma. In 2022, PIVOT IO-001 (melanoma), PIVOT-09 (RCC), and PIVOT-10 (urothelial) all failed to improve response, PFS, or OS over nivolumab alone; BMS and Nektar ended the collaboration (BMS had paid $1.85B upfront in 2018).
Lesson: single-arm combination response rates in melanoma are unreliable because nivolumab alone already produces them; biological rationale (Treg sparing) did not translate.
Backbone ribbon from PDB 1M47. RCSB PDB 1M47. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
IL-2 with releasable PEG chains; preferential CD122 (IL-2Rβγ) engagement.
1.Bempegaldesleukin binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bempegaldesleukin" OR ABSTRACT:"Bempegaldesleukin" OR TITLE:"NKTR-214" OR ABSTRACT:"NKTR-214" OR TITLE:"bempeg" OR ABSTRACT:"bempeg") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bempegaldesleukin, not a curated reading list.
Shares T-cell exhaustion, Failures are hidden and the tag failure.
Shares Failures are hidden, Melanoma and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.